Efficient Synthesis of Phospholipids from Glycidyl ... - ACS Publications

Dec 6, 2001 - ... are anchored to a self-assembled monolayer (SAM) contg. synthetic chelator ...... Jan Lindberg , Stefan C.T Svensson , Peter Påhlsso...
0 downloads 0 Views 87KB Size
194

J. Org. Chem. 2002, 67, 194-199

Efficient Synthesis of Phospholipids from Glycidyl Phosphates Jan Lindberg, Johan Ekeroth, and Peter Konradsson* Department of Chemistry, Linko¨ ping University, SE-581 83 Linko¨ ping, Sweden [email protected] Received July 23, 2001

New efficient routes to enantiopure phospholipids, starting from (S)-glycidol, are described. Lysophosphatidic acids and phosphatidic acids were obtained in good overall yields from (S)-glycidol, in only three and four steps, respectively. Moreover, the strategy can also be used to produce phosphatidylcholines in three steps. Using dialkylphosphoramidites, (S)-glycidol was phosphorylated to give (R)-1-O-glycidyl dialkyl phosphates. Regiospecific epoxide opening, using hexadecanol or cesium palmitate, followed by phosphate deprotection, provided lysophosphatidic acids. 2-OEsterification prior to phosphate deprotection provided 1,2-O-diacyl and 1-O-alkyl-2-O-acyl phosphatidic acids. Phosphorylation of (S)-glycidol using phosphorus oxychloride followed by in situ treatment with choline tosylate produced (R)-glycidyl phosphocholine. Subsequent nucleophilic opening of the epoxide using cesium palmitate produced 1-O-palmitoyl-sn-glycero-3-phosphocholine, which has been used in syntheses of phosphatidylcholines. Introduction Phospholipids, especially phosphatidylcholine and phosphatidylethanolamine, are major constituents of cell membranes. Many phospholipids possess biological activity,1-4 examples are the hormone platelet activating factor (PAF) and lysophosphatidic acid (LPA)3-5 (Figure 1). For these lipids, the mechanisms of action are not fully understood. By modification of different parts of the lipid, activity varies from one biological process to the other.5-7 In addition to structure-activity studies, recent advances in the construction of artificial cell membranes with specific biological functions demand tailor-made glycerolderived lipids.8 In this paper we present efficient methods for synthesis of various phospholipids and analogues thereof, starting from enantiomerically pure (S)-glycidol. Up to date several routes to glycerophospholipids have been presented,9-12 most of them involving derivatization and protecting group manipulations of various selectively protected glycerol derivatives. Methods, for preparing (1) Snyder, F.; Lee, T.-C.; Blank, M. L. Ann. N.Y. Acad. Sci. 1989, 568, 35-43. (2) Racke´, K.; Hammermann, R.; Juergens, U. R. Pulm. Pharmacol. Ther. 2000, 13, 99-114. (3) Lynch, K. R.; Hopper, D. W.; Carlisle, S. J.; Catalano, J. G.; Zhang, M.; MacDonald, T. L. Mol. Pharmacol. 1997, 52, 75-81. (4) Hopper, D. W.; Ragan, S. P.; Hooks, S. B.; Lynch, K. R.; Macdonald, T. L. J. Med. Chem. 1999, 42, 963-970. (5) Bandoh, K.; Aoki, J.; Hosono, H.; Kobayashi, S.; Kobayashi, T.; Murakami-Murofushi, K.; Tsujimoto, M.; Arai, H.; Inoue, K. J. Biol. Chem. 1999, 274, 27776-27785. (6) Gueguen, G.; Gaige, B.; Grevy, J. M.; Rogalle, P.; Bellan, J.; Wilson, M.; Klaebe, A.; Pont, F.; Simon, M. F.; Chap, H. Biochemistry 1999, 38, 8440-8450. (7) Sugiura, T.; Nakane, S.; Kishimoto, S.; Waku, K.; Yoshioka, Y.; Tokumura, A.; Hanahan, D. J. Biochim. Biophys. Acta 1999, 1440, 194-204. (8) Stora, T.; Dienes, Z.; Vogel, H.; Duschl, C. Langmuir 2000, 16, 5471-5478. (9) Eibl, H. Chem. Phys. Lipids 1980, 26, 405-429. (10) Eibl, H. Angew. Chem., Int. Ed. Engl. 1984, 23, 257-271. (11) Ramirez, F.; Marecek, J. F. Synthesis 1985, 449-488. (12) Martin, S. F.; Josey, J. A.; Wong, Y.-L.; Dean, D. W. J. Org. Chem. 1994, 59, 4805-4820.

optically active phosphatidylcholine, PAF, and analogues thereof, starting from racemic glycidol and epichlorohydrin,13 the commercially available (S)-glycidol, or (R)glycidyl tosylate have been published.14-17 Glycidol derivatives, in the form of glycidyl glycosides, have also been used in syntheses of glycosyl glycerolipids.18-20 The methods involving epoxide opening of enantiopure glycidols have been shown to proceed regiospecifically, and without significant loss of optical purity. Up to date, however, these methods involve protecting group manipulations after epoxide opening. Surprisingly, direct phosphorylation of glycidol and subsequent opening of the epoxide, has not been published. This approach provides an efficient route, without tedious protecting group manipulations, to various biologically important phospholipids, and analogues thereof. Results and Discussion In the routes leading to phosphatidic acids, phosphorylations were performed with two different dialkyl phosphoramidites, dibenzyl-N,N-diisopropyl, and di-tertbutyl-N,N-diisopropyl phosphoramidite. The amidites were synthesized using known methods.21-24 The phosphitylation of (S)-glycidol using dibenzyl-N,N-diisopropyl phosphoramidite and subsequent oxidation using m(13) Cimetiere, B.; Jacob, L.; Julia, M. Bull. Soc. Chim. Fr. 1991, 6, 926-938. (14) Ali, S.; Bittman, R. J. Org. Chem. 1988, 53, 5547-5549. (15) Guivisdalsky, P. N.; Bittman, R. J. Org. Chem. 1989, 54, 46434648. (16) Guivisdalsky, P. N.; Bittman, R. J. Org. Chem. 1989, 54, 46374642. (17) Burgos, C. E.; Ayer, D. E.; Johnson, R. A. J. Org. Chem. 1987, 52, 4973-4977. (18) Bellucci, G.; Catelani, G.; Chiappe, C.; D’Andrea, F.; Grigo`, G. Tetrahedron Asym. 1997, 8, 765-773. (19) Suhr, R.; Scheel, O.; Thiem, J. J. Carbohydr. Chem. 1998, 17, 937-968. (20) Nishida, Y.; Ohrui, H.; Meguro, H.; Ishizawa, M.; Matsuda, K.; Taki, T.; Handa, S.; Yamamoto, N. Tetrahedron Lett. 1994, 35, 54655468. (21) Nurminen, E. J.; Mattinen, J. K.; Lo¨nnberg, H. J. Chem. Soc., Perkin Trans. 2 1998, 1621-1628.

10.1021/jo010734+ CCC: $22.00 © 2002 American Chemical Society Published on Web 12/06/2001

Synthesis of Phospholipids from Glycidyl Phosphates

J. Org. Chem., Vol. 67, No. 1, 2002 195

Figure 1. Efficient and short synthetic routes from commercially available (S)-glycidol to many bioactive and/or naturally occurring glycerophospholipids, developed in this work.

Scheme 1

CPBA, produced the phosphorylated glycidol derivative 1 in 89% yield (Scheme 1). Lewis acid-catalyzed epoxide opening of the corresponding tosylate, using hexadecanol and BF3, has been shown to proceed regio- and stereospecifically.15 Opening of the epoxide in 1 using similar conditions proceeded with complete regiospecificity to produce the dibenzyl-protected lysoalkyl phosphatidic acid 2 in 67% yield. Deprotection of the phosphate gave compound 3, in 53% overall yield from (S)-glycidol. DCCpromoted esterification of 2 with palmitic acid in almost quantitative yield, and subsequent debenzylation of the phosphate produced the 1-O-alkyl-2-O-acyl-phosphatidic acid 5, in 40% overall yield from (S)-glycidol. Attempts to produce 1-O-acyl-3-O-dibenzylphosphorylsn-glycerols by nucleophilic opening of the epoxide 1 using cesium palmitate produced only decomposed material and benzyl palmitate, due to carboxylate attack on the benzyl groups. At this stage our attention was turned to other phosphate protecting groups, not so easily attacked by nucleophiles. The tert-butyl group seemed (22) Tanaka, T.; Tamatsukuri, S.; Ikehara, T. Tetrahedron Lett. 1986, 27, 199. (23) Ullman, E.; Engels, J. Tetrahedron Lett. 1986, 27, 1023. (24) Kuo-Long, Y.; Fraser-Reid, B. Tetrahedron Lett. 1988, 29, 979982.

Scheme 2

like a reasonable choice. Di-tert-butyl-N,N-diisopropyl phosphoramidite was used for the oxidative phosphorylation of (S)-glycidol to produce (R)-di-tert-butyl-phosphorylglycidol 6 in 74% yield (Scheme 2). Regioselective opening of the epoxide with cesium palmitate produced 7a in 71% yield along with minor amounts of the regioisomeric 3-O-di-tert-butylphosphoryl-2-O-palmitoylsn-glycerol. Esterification of 7a with oleic acid produced the di-tertbutyl protected mixed 1,2-diacyl phosphatidic acid 8 in 87% yield. Treatment of 7a and 8 with TFA in CH2Cl2 cleanly produced the deprotected lysophosphatidic acid 9 and the mixed 1,2-diacyl phosphatidic acid 10 in quantitative yields. The overall yields were 53% and 46%, respectively. Besides from being present in biological membranes, these types of compounds have been used in syntheses of phosphatidylcholines and phosphatidyl ethanolamines, by coupling with various choline- and ethanolamine derivatives.14,25-28 To find a shorter route to choline derivatives, (S)glycidol was phosphorylated using phosphorus oxychlo-

196

J. Org. Chem., Vol. 67, No. 1, 2002

Lindberg et al. Scheme 3

Scheme 4

ride. Subsequent in situ treatment with choline tosylate produced the choline derivative 11 in 53% yield. Nucleophilic opening of the epoxide using cesium palmitate produced lysophosphatidylcholine 12 (Scheme 3), which has been used in syntheses of phosphatidylcholine.13,29,30 The minor amounts of the regioisomeric 2-O-palmitoyl derivative, produced in the nucleophilic opening of the epoxide in Scheme 2, was thought to be the result of acyl migration from the primary position. There is, of course, a possibility that part of the product is a result of nucleophilic attack on the secondary carbon, followed by equilibration of the regioisomers as depicted in Scheme 4. This would give a partially racemized product. Therefore the optical purity of 7a had to be evaluated. 7a was converted to Mosher’s acid derivative 13a (Figure 2) by treatment with (R)-R-methoxy-R-(trifluoromethyl)phenylacetic acid chloride ((R)-Mosher’s acid chloride) in pyridine. The enantiomeric 7b was synthesized analogously from (R)-glycidol, and derivatized with (R)-Mosher’s acid to produce 13b (Figure 2). The optical purity was determined by 1H and 19F NMR. The double doublet at 4.38 ppm in 13a (Figure 2B) shifted to 4.48 in 13b (Figure 2D) and the trifluoromethyl peak from 104.44 to 104.36 (Figures 2A and 2C). Only traces of the double doublet at 4.48 ppm in Figure 2B and the double doublet at 3.38 in Figure 2D could be detected, indicating that no loss of optical purity had occurred. The 19F spectra (Figures 2A and 2C) indicated >96% ee. Considering the optical purity of the starting compouds, (S)-glycidol (98% ee) and (R)-Mosher’s acid chloride (99% ee), no significant loss of optical purity is observed. (25) Aneja, R.; Chadha, J. S.; Davies, A. P. Tetrahedron Lett. 1969, 48, 4183-4186. (26) Rakhit, S.; Bagli, J. F.; Deghenghi, R. Can. J. Chem. 1969, 47, 2906-2910. (27) Bersch, B.; Starck, J. P.; Milon, A.; Nakatani, Y.; Ourisson, G. Bull. Soc. Chim. Fr. 1993, 130, 575-583. (28) Akita, H.; Umezawa, I.; Matsukura, H.; Oishi, T. Chem. Pharm. Bull. 1992, 40, 318-324. (29) Xia, J.; Hui, Y.-Z. Tetrahedron Asym. 1997, 8, 451-458. (30) Vodovozova, E. L.; Molotkovsky, J. G. Tetrahedron Lett. 1994, 35, 1933-1936.

Conclusions Both natural and unnatural enantiomers of a broad range of biologically important phospholipids, and analogues thereof, can be obtained in high optical purity from commercially available (S)- or (R)-glycidol. The routes are short and efficient and proceed in good overall yields. Phosphorylation of (S)-glycidol using dialkyl phosphoramidites, followed by opening of the epoxide, using alcohol or cesium carboxylate, and subsequent phosphate deprotection is an effective route to enantiopure lysophosphatidic acids. Moreover, 2-O-esterification of the lysophosphatidic acids prior to phosphate deprotection, provides phosphatidic acids in only four steps. Variation of the phosphorylation procedure enables synthesis of other classes of phospholipids. Phosphorylation of (S)-glycidol using phosphorus oxychloride followed by in situ treatment with choline tosylate, and subsequent nucleophilic opening of the epoxide using cesium palmitate, produced the lysophosphatidylcholine 1-O-Palmitoyl-sn-glycero-3-phosphocholine, which has been used in syntheses of phosphatidylcholines.13,29,30

Experimental Section General Methods. Organic phases were dried over MgSO4, filtered, and concentrated in vacuo below 40 °C. TLC: 0.25 mm precoated silica gel plates (MERCK silica gel 60F254); Detection by spraying the plates with AMC solution [(NH4)2MoO4 100 g and Ce(IV)SO4 2 g dissolved in 10% H2SO4, 2 L] followed by heating at ∼250 °C. Optical rotations were recorded at room temperature with a Perkin-Elmer 241 polarimeter. Melting points were recorded with a Gallenkamp melting point apparatus. Flash chromatography (FC): Silica gel MERCK 60 (0.040-0.063 mm). 1H and 13C NMR spectra were recorded on a Varian Mercury 300 at 300 MHz (1H), 75 MHz (13C), 121 MHz (31P) and 282 MHz (19F), temp 25 °C. Chemical shifts are given in ppm with TMS as internal standard (δ ) 0.00); 31P, 85% H3PO4 (δ ) 0.00); 19F, CFCl3 (δ ) 0.00). MALDI-TOF mass-spectra were recorded with a Voyager-DE STR Biospectrometry Workstation, in positive mode, using an R-cyano-4-hydroxycinnamic acid matrix. (S)glycidol (98% ee) and (R)-glycidol (98% ee) were purchased from Aldrich. (R)-R-methoxy-R-(trifluoromethyl)phenylacetic acid chloride (99% ee) was purchased from Fluka.

Synthesis of Phospholipids from Glycidyl Phosphates

Figure 2.

1

H and

J. Org. Chem., Vol. 67, No. 1, 2002 197

19

F NMR spectra of the (S)-Mosher’s acid derivatives 13a (A+B) and 13b (C+D).

(R)-Dibenzylphosphorylglycidol (1). To a stirred solution of (S)-glycidol (253 mg, 3.42 mmol) and dibenzyl-N,Ndiisopropyl phosphoramidite (2.50 g, 6.92 mmol) in CH2Cl2 (100 mL) was added 1H-tetrazole (800 mg, 11.4 mmol). After 30 min, the mixture was cooled to 0 °C and m-CPBA (1.75 g, 10 mmol) was added. The mixture was stirred for 40 min, washed with 10% aqueous Na2S2O3 and NaHCO3 (sat.), dried, filtered, and concentrated. FC (toluene/EtOAc 3:2, 1% NEt3) gave 1 as a colorless oil (1.02 g, 3.05 mmol, 89%). Rf 0.38 (toluene/EtOAc 1:1); [R]D -8.9 (c 0.88, CHCl3); 1H and 13C NMR spectra were identical to those published for the racemic compound.31 3-O-Dibenzylphosphoryl-1-O-hexadecyl-sn-glycerol (2). To a solution of 1 (80 mg, 0.24 mmol) and hexadecanol 116 mg, 0.48 mmol) in CH2Cl2 (3 mL) was added a 10% v/v solution of BF3-diethyl ether complex in CH2Cl2 (40 µL). After 10 h, the mixture was concentrated. FC (toluene/EtOAc 2:1) of the

residue gave crystalline 2 (93 mg, 0.16 mmol, 67%). Rf 0.43 (toluene/EtOAc 1:1): mp 44-45 °C (from hexane); [R]D -2.7 (c 1.1, CHCl3); NMR (CDCl3): 1H, δ 0.88 (t, 3H, J ) 6.4 Hz), 1.26 (br, 26H), 1.53 (m, 2H), 3.37-3.42 (m, 4H), 3.87-4.13 (m, 3H), 5.05 (d, 2H, J ) 8.4 Hz), 5.05 (d, 2H, J ) 8.4 Hz), 7.34 (br, 10H); 13C, δ 14.1, 22.7, 26.1, 29.3, 29.5, 29.6, 29.7, 31.9, 69.1 (d, J ) 5.5 Hz), 69.3 (d, J ) 7.4 Hz), 70.7, 71.7, 128.0, 128.6, 135.7 (d, J ) 5.5 Hz); 31P, δ 0.58; Anal. Calcd for C33H53O6P: C 68.7; H 9.3 Found C 68.8; H 8.9. 1-O-Hexadecyl-3-O-phosphoryl-sn-glycerol (3). A mixture of 2 (26 mg, 0.045 mmol) and 10% Pd on carbon (18 mg) in EtOAc (2 mL) was stirred under H2 (1 atm) for 2 h, filtered through Celite, and concentrated to yield crystalline 3 (16 mg, 0.040 mmol, 90%). Rf 0.12 (CHCl3/MeOH/H2O 65:25:4); mp. 66-67 °C (CHCl3); [R]D -2.0 (c 1.1, DMSO); 1H and 13C NMR spectra were identical to those published for the racemic compound.32

(31) De Viguerie, N. L.; Willson, M.; Pe´rie´, J. New J. Chem. 1994, 18, 1183-1195.

(32) Malekin, S. I.; Khromova, N. Y.; Kisin, A. V.; Kruglyak, Y. L.; Kurochkin, V. K. Russ. J. Bioorg. Chem. 1997, 23, 677-682.

198

J. Org. Chem., Vol. 67, No. 1, 2002

3-O-Dibenzylphosphoryl-1-O-hexadecyl-2-O-palmitoylsn-glycerol (4). A solution of 2 (40 mg, 0.069 mmol), palmitic acid (28 mg, 0.11 mmol), dicyclohexylcarbodiimide (23 mg, 0.11 mmol), and 4-(dimethylamino)pyridine (1 mg, 0.008 mmol) in CH2Cl2 (2 mL) was stirred for 22 h, filtered through Celite, and concentrated. FC (toluene/EtOAc 8:1) of the residue gave crystalline 4 (54 mg, 0.066 mmol, 96%). Rf 0.27 (toluene/EtOAc 8:1); mp 37-38 °C (from ethanol); [R]D -3.1 (c 1.0, CHCl3); NMR (CDCl3): 1H, δ 0.88 (m, 6H), 1.25 (br, 52H), 1.45-1.62 (m, 4H), 2.27, (t, 2H, J ) 7.7 Hz), 3.35-3.41 (m, 2H), 3.49 (d, 2H, J ) 5.5 Hz), 4.08-4.23 (m, 2H), 5.03 (d, 2H, J ) 8.0 Hz), 5.04 (d, 2H, J ) 8.0 Hz), 5.11 (m, 1H), 7.34 (br, 10H); 13C, δ 14.1, 22.7, 24.9, 26.1, 29.1, 29.3, 29.4, 29.7, 31.9, 34.3, 66.1 (d, J ) 5.5 Hz), 68.3, 69.3, 69.4. 70.6 (d, J ) 7.4 Hz), 71.8, 127.9, 128.5, 128.6, 135.8 (d, J ) 7.4 Hz), 173.1; 31P, δ 0.53. Anal. Calcd for C49H83O7P: C 72.2; H 10.3. Found: C 72.2; H 10.1. 1-O-Hexadecyl-2-O-palmitoyl-3-O-phosphoryl-sn-glycerol (5). A mixture of 4 (33 mg, 0.040 mmol) and 10% Pd on carbon (14 mg) in EtOAc (2 mL) was stirred under H2 (1 atm) for 2 h, filtered through Celite, and concentrated to yield crystalline 5 (20 mg, 0.032 mmol, 78%). Rf 0.36 (CHCl3/MeOH/ H2O 65:25:4); mp 78-80 °C (from EtOAc/hexane); [R]D -1.3 (c 1.7, CHCl3); 1H and 13C NMR of the pyridinium salt were in accordance with those published for the racemic compound.33 (R)-Di-tert-butylphosphorylglycidol (6). To a stirred solution of (S)-glycidol (238 mg, 3.21 mmol) and di-tert-butylN,N-diisopropyl phosphoramidite (1.58 g, 5.70 mmol) in CH2Cl2 (100 mL) was added 1H-tetrazole (760 mg, 10.9 mmol). After 30 min, the mixture was cooled to 0 °C and m-CPBA (1.70 g, 9.85 mmol) was added. The mixture was stirred for 40 min, washed with 10% aqueous Na2S2O3 and NaHCO3 (sat.), dried, filtered, and concentrated. FC (gradient petroleum ether 65-75/EtOAc 3:1 f 1:1, 0.1% NEt3) gave 6 as a colorless oil (635 mg, 2.38 mmol, 74%). Rf (toluene/EtOAc 1:1) 0.24; [R]D -5.0 (c 1.1, CHCl3); 1H NMR (CCl4) were in accordance with that published for the racemic compound.34 NMR (CDCl3): 1H, δ 1.52 (s, 18H), 2.68 (dd, 1H, J ) 4.7, 2.6 Hz), 2.84 (dd, 1H, J ) 4.6, 4.6 Hz), 3.25 (m, 1H), 3.91 (ddd, 1H, J ) 11.7, 8.0, 5.8 Hz), 4.19 (ddd, 1H, J ) 11.7, 3.3, 6.9); 13C, δ 29.9 (d, J ) 3.7 Hz), 44.7, 50.2 (d, J ) 9.2 Hz), 67.4 (d, J ) 5.6 Hz), 82.8 (d, J ) 3.8 Hz), 83.0 (d, J ) 3.7); 31P, δ -9.09. 3-O-Di-tert-butylphosphoryl-1-O-palmitoyl-sn-glycerol (7a). A mixture of 6 (127 mg, 0.48 mmol), cesium palmitate (557 mg, 1.43 mmol), and palmitic acid (122 mg, 0.48 mmol) in DMF (5 mL) was stirred at 80 °C. After 10 h, the mixture was allowed to attain room temperature, and the precipitate filtered off. Concentration and FC (toluene/EtOAc 2:1 1% NEt3) gave 7a as a waxy solid (178 mg, 0.34 mmol, 71%). Rf 0.52 (toluene/EtOAc 1:3); [R]D -1.7 (c 1.5, CHCl3); NMR (CDCl3): 1H, δ 0.88 (t, 3H, J ) 6.6 Hz), 1.26 (br, 26H), 1.50 (s, 18H), 1.62 (m, 2H), 2.34 (t, 2H, J ) 7.5 Hz), 3.984.17 (m, 5H); 13C, δ 14.1, 22.7, 24.9, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 29.8, 29.9, 31.9, 34.2, 64.5, 68.2 (d, J ) 7.4 Hz), 68.9 (d, J ) 5.5 Hz), 83.2 (d, J ) 7.4 Hz), 173.8; 31P, δ -7.32. Anal. Calcd for C27H55O7P: C 62.0; H 10.6. Found: C 61.9; H 10.4. 3-O-Di-tert-butylphosphoryl-2-O-oleoyl-1-O-palmitoylsn-glycerol (8). A solution of 7a (51 mg, 0.098 mmol), oleic acid (74 mg, 0.26 mmol), dicyclohexylcarbodiimide (54 mg, 0.262 mmol), and 4-(dimethylamino)pyridine (2 mg, 0.016 mmol) in CH2Cl2 (3 mL) was stirred for 20 h, filtered through Celite, and concentrated. FC (toluene/EtOAc 8:1, 0.1% NEt3) gave 8 (67 mg, 0.085 mmol, 87%) as a colorless syrup. Rf 0.32 (toluene/EtOAc 4:1); [R]D +4.9 (c 0.9, CHCl3); NMR (CDCl3): 1H, δ 0.88 (m, 6H), 1.26 (br, 48H), 1.48 (s, 18H), 1.61 (m, 4H), 2.01 (m, 4H), 2.31 (t, 2H, J ) 7.5 Hz), 2.32 (t, 2H, J ) 7.5 Hz), 4.05-4.10 (m, 2H), 4.17 (dd, 1H, J ) 11.9, 6.0 Hz), 4.36 (dd, 1H, J ) 11.9, 4.2 Hz), 5.18-5.41 (m, 3H); 13C, δ 14.1, 22.7, 24.9, 27.2, 27.3, 29.1, 29.2, 29.3, 29.5, 29.6, 29.7, 29.8, 29.9, 31.9, 34.1, 34.2, 62.0, 64.4 (d, J ) 5.5 Hz), 69.6 (d, J ) 9.2 Hz), 82.7 (d, J ) 7.4 Hz), 82.8 (d, J ) 7.4 Hz), 129.7, 130.0, (33) Malekin, S. I.; Kruglyak, Y. L.; Khromova, N. Y.; Aksenova, M. Y.; Sokolov, V. P. Russ. J. Bioorg. Chem. 1997, 23, 591-596. (34) Kluba, M.; Zwierak, A. Roczniki Chem. 1974, 48, 1603-1608.

Lindberg et al. 172.9, 173.3; 31P, δ -9.02. Anal. Calcd for C45H87O8P: C 68.7; H 11.1. Found: C 68.3; H 11.0. 1-O-Palmitoyl-3-O-phosphoryl-sn-glycerol (9). To 7a (37 mg, 0.071 mmol) in CH2Cl2 (8 mL) was added TFA (2 mL). After 10 min was added MeOH (0.10 mL). After an additional 10 min, the mixture was diluted with toluene (20 mL) and concentrated to yield crystalline 9 (29 mg, 0.071 mmol, quant.). Rf 0.12 (CHCl3/MeOH/H2O 65:25:4); mp 79-80 °C (from CHCl3); [R]D +5.0 (c 0.54, DMSO), lit.35 (sodium salt, CHCl3) [R]D +13.2; NMR (DMSO): 1H, δ 0.84 (t, 3H, J ) 5.8 Hz), 1.22 (br, 24H), 1.50 (m, 2H), 2.28 (t, 2H, J ) 7.4 Hz), 3.72-3.85 (m, 3H), 3.93 (dd, 1H, J ) 11.2, 5.6 Hz), 4.02 (dd, 1H, J ) 11.2, 4.1 Hz); 13C, δ 13.8, 22.0, 24.3, 28.4, 28.59, 28.61, 28.8, 28.89, 28.94, 31.2, 33.3, 64.7, 66.1 (d, J ) 5.4 Hz), 67.2 (d, J ) 8.0 Hz), 172.7; 31P, δ 0.25; MALDI-TOF Calcd for C19H39O7P: [M + Na]+ 433.2. Found: [M + Na]+ 433.2. 2-O-Oleoyl-1-O-palmitoyl-3-O-phosphoryl-sn-glycerol (10). To 8 (32 mg, 0.041 mmol) in CH2Cl2 (8 mL) was added TFA (2 mL). After 10 min was added MeOH (0.1 mL). After an additional 10 min, the mixture was diluted with toluene (20 mL) and concentrated to yield 10 (28 mg, 0.041 mmol, quant.). Rf 0.64 (CHCl3/MeOH/H2O 65:25:4); mp diammonium salt 185-187 °C (from CHCl3/Acetone), lit.36 192-194 °C; [R]D +7.2 (c 3.0, CHCl3), lit.36 [R]D +4.5; NMR (CDCl3/CD3OD 4:1): 1H, δ 0.81-0.91 (m, 6H), 1.2-1.4 (m, 48H), 1.55-1.68 (m, 4H), 1.97-2.06 (m, 4H), 2.30-2.37 (m, 6H), 4.08-4.12 (m, 2H), 4.19 (dd, 1H, J ) 12.1, 6.3 Hz), 4.38 19 (dd, 1H, J ) 12.0, 3.7 Hz), 5.20-5.26 (m, 1H), 5.32-5.37 (m, 2H); 13C, δ 14.2, 22.9, 25.1, 27.4, 29.3-30.0, 32.1, 34.3, 34.4, 62.4, 64.5 (d, J ) 5.2 Hz), 70.1 (d, J ) 7.4 Hz), 129.9, 130.2, 173.7, 174.2; 31P (CDCl3), δ 1.62. (R)-Glycidyl Phosphocholine (11). To a stirred solution of (S)-glycidol (670 mg, 9.04 mmol) and ethyl N,N-diisopropylamine (6.5 mL, 9.5 mmol) in CHCl3 (20 mL) at 0 °C under an argon atmosphere was added phosphorus oxychloride (1.40 g, 9.13 mmol). After 2 h, pyridine (2.0 mL) and choline tosylate (2.89 g, 10.5 mmol) were added, and the mixture was allowed to attain room temperature. After an additional 5 h, water was added (0.50 mL), and the stirring was continued for an additional 1 h. Concentration and FC (70% EtOH) gave 11 (1.14 g, 4.76 mmol, 53%). Rf 0.19 (70% EtOH); [R]D -15 (c 1.8, MeOH); NMR (CD3OD): 1H, δ 2.68 (dd, 1H, J ) 5.0, 2.7 Hz), 2.82 (dd, 1H, J ) 5.0, 4.1 Hz), 3.21-3.26 (m, 1H), 3.24 (s, 9H), 3.65-3.70 (m, 3H), 4.19 (ddd, 1H, J ) 12.0, 6.9, 2.5 Hz), 4.264.33 (m, 2H); 13C, δ 45.0, 52.0 (d, J ) 8.3 Hz), 54.6, 54.7, 54.8, 60.4 (d, J ) 5.2 Hz), 67.5, 67.7 (d, J ) 5.4 Hz); 31P, δ 0.47; MALDI-TOF Calcd for C8H19NO5P: [M + H]+ 240.1. Found: [M + H]+ 240.1. 1-O-Palmitoyl-sn-glycero-3-phosphocholine (12). A mixture of 11 (107 mg, 0.45 mmol), cesium palmitate (174 mg, 0.45 mmol) and palmitic acid (115 mg, 0.55 mmol) in DMF (5 mL) was stirred at 80 °C. After 26 h, the mixture was concentrated. FC (MeOH/H2O 5:1) gave crystalline 12 (143 mg, 0.29 mmol, 65%). Rf 0.29 (MeOH/H2O 5:1); mp 250-253 °C (from MeOH), lit.37 243-245 °C; [R]D -2.8 (c 7.7, CHCl3/MeOH 9:1), lit. for the enantiomer 3-O-palmitoyl-sn-glycero-1-phosphocholine.37 [R]D +2.8; 1H and 13C NMR spectra were identical to those previously published.38 31P (CD3OD), δ 1.22. 3-O-Di-tert-butylphosphoryl-2-O-[(S)-R-methoxy-R-(trifluoromethyl)phenylacetyl]-1-O-palmitoyl-sn-glycerol (13a). A solution of 7a (17 mg, 0.033 mmol) and (R)-R-methoxyR-(trifluoromethyl)phenylacetic acid chloride (32 mg, 0.13 mmol) in pyridine (2 mL) was stirred for 21 h. The mixture was diluted with CH2Cl2, washed with aqueous NaHCO3, dried, filtered, and concentrated. FC (toluene f toluene/EtOAc 2:1 0.1% NEt3) gave 13a as a white solid (23 mg, 0.31 mmol, (35) Stoffel, W.; Wolf, G. D. Hoppe-Seyler’s Z. Physiol. Chem. 1966, 347, 94-101. (36) Molotkowsky, J. G.; Nikulina, L. F.; Bergelson, L. D. Chem. Phys. Lipids 1976, 17, 108-110. (37) Eibl, H.; Westphal, O. Liebings Ann. Chem. 1970, 738, 161169. (38) Noda, N.; Tanaka, R.; Nishi, M.; Inoue, S.; Miyahara, K. Chem. Pharm. Bull. 1993, 41, 1366-1368.

Synthesis of Phospholipids from Glycidyl Phosphates 96%). Rf 0.44 (toluene/EtOAc 2:1); NMR: 1H (CDCl3), δ 0.88 (t, 3H, J ) 6.6 Hz), 1.26 (br, 24H), 1.46 (br, 20H), 2.22 (t, 2H, J ) 8.1 Hz), 3.58 (s, 3H), 4.05-4.24 (m, 3H), 4.38 (dd, 1H, J ) 4.0, 12.4 Hz), 5.51 (m, 1H), 7.40 (m, 3H), 7.54 (m, 2H); 19F (CCl4), δ 104.36. 1-O-Di-tert-butylphosphoryl-2-O-[(S)-R-methoxy-R-(trifluoromethyl)phenylacetyl]-3-O-palmitoyl-sn-glycerol (13b). 13b was synthesized by the same method as 13a,

J. Org. Chem., Vol. 67, No. 1, 2002 199 starting from (R)-glycidol. Rf 0.44 (toluene/EtOAc 2:1); NMR: 1H (CDCl ), δ 0.88 (t, 3H, J ) 7.0 Hz), 1.25 (br, 24H), 1.44 (br, 3 20H), 2.28 (t, 2H, J ) 7.7 Hz), 3.57 (s, 3H), 4.0-4.25 (m, 3H), 4.48 (dd, 1H, J ) 3.3, 12.1 Hz), 5.51 (m, 1H), 7.41 (m, 3H), 7.55 (m, 2H); 19F (CCl4), δ 104.44. JO010734+